Larotrectinib was the next drug to receive tumour-agnostic approval and entrectinib, an inhibitor of TRK, ROS1 and ALK, was FDA approved in 2019 for selected patients aged >12 years with NTRK fusions and adults with metastatic non-small-cell lung cancer whose tumours are ROS1 positive.2 Entrectinib was granted EMA Priority Medicines Designation in October 2017, potentially accelerating assessment of its European Marketing Authorisation Application and is currently being tested in paediatric patients with NTRK and ROS aberrations (NCT02650401). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.